Is Selling Anthera Pharmaceuticals, Inc. (ANTH) Here a Winning Strategy?

May 21, 2018 - By Marguerite Chambers

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Logo

The stock of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) hit a new 52-week low and has $0.27 target or 5.00 % below today’s $0.29 share price. The 5 months bearish chart indicates high risk for the $7.54 million company. The 1-year low was reported on May, 21 by If the $0.27 price target is reached, the company will be worth $376,850 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 0.38% or $0.0011 during the last trading session, reaching $0.2879. About 226,013 shares traded. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has declined 90.50% since May 21, 2017 and is downtrending. It has underperformed by 102.05% the S&P500.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Coverage

Among 3 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Anthera Pharmaceuticals had 5 analyst reports since January 22, 2018 according to SRatingsIntel. The firm has “Hold” rating by Jefferies given on Tuesday, March 6. The rating was maintained by Piper Jaffray on Monday, January 22 with “Buy”. Jefferies maintained Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) rating on Tuesday, February 13. Jefferies has “Hold” rating and $1.75 target. The company was downgraded on Monday, March 12 by Piper Jaffray.

More news for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) were recently published by:, which released: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” on May 17, 2018.‘s article titled: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” and published on May 18, 2018 is yet another important article.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company has market cap of $7.54 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. It currently has negative earnings.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: